

UPDATE FROM TEVA

YOUR GLOBAL ADVANTAGE

The Teva logo is a green circle containing the word "TEVA" in white, stylized, uppercase letters.

Teva's acquisition of ratiopharm is now complete

August 10, 2010

I am pleased to announce that Teva's acquisition of ratiopharm was completed today.

The combination of Teva Canada and ratiopharm—who, as respected competitors, have shared a common set of values for many years—will result in a new, stronger Teva in Canada.

Our shared values include our vision to increase and accelerate Canadians' access to safe, high-quality, affordable medications; to provide reliable service to our customers; and to deliver more value to our many stakeholders. Harnessing the strengths of both organizations, we intend to enhance our product development and supply chain, and expand our product offerings in Canada.

This acquisition makes us the #1 generic pharmaceutical company in the European market.

Together, in Canada we will:

- Provide products used to fill over 70 million generic prescriptions annually;
- Supply over 300 products to the Canadian market;
- Manufacture over 6 billion tablets/capsules per year in our four Canadian plants;
- Employ nearly 2,000 Canadians;
- Broaden our offerings in areas such as narcotics, topicals and OTC products.

The acquisition of ratiopharm is another milestone in the global growth of Teva and will further contribute to Teva's ongoing leadership in the development, manufacture and sale of generic pharmaceutical products. In Canada, we look forward to making this global advantage work for our customers, employees and other stakeholders.

I will continue to keep you informed about the progress of the integration and the exciting opportunities that lie ahead.

Regards,

A handwritten signature in blue ink, appearing to read "Barry".

Barry Fishman
President & CEO